{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:20:21Z","timestamp":1789885221079,"version":"4.0.1"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T00:00:00Z","timestamp":1456444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0150146","type":"journal-article","created":{"date-parts":[[2016,2,26]],"date-time":"2016-02-26T18:55:43Z","timestamp":1456512943000},"page":"e0150146","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine"],"prefix":"10.1371","volume":"11","author":[{"given":"Nuriban","family":"Valero-Pacheco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"P\u00e9rez-Toledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Villas\u00eds-Keever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"N\u00fa\u00f1ez-Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Bosc\u00f3-G\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Lozano-Dubernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horacio","family":"Lara-Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Alpuche-Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Bonifaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Arriaga-Pizano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Pastelin-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Isibasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantino","family":"L\u00f3pez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,2,26]]},"reference":[{"issue":"9397","key":"ref1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/S0140-6736(03)14854-4","article-title":"Influenza","volume":"362","author":"KG Nicholson","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1128\/CMR.00097-12","article-title":"Traditional and new influenza vaccines","volume":"26","author":"SS Wong","year":"2013","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/hv.18757","article-title":"Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic","volume":"8","author":"C Lopez-Macias","year":"2012","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/wnan.119","article-title":"Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design","volume":"3","author":"EM Plummer","year":"2011","journal-title":"Wiley interdisciplinary reviews Nanomedicine and nanobiotechnology"},{"issue":"1\u20132","key":"ref5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0264-410X(01)00312-7","article-title":"Antibody responses to preS components after immunization of children with low doses of BioHepB","volume":"20","author":"K Madalinski","year":"2001","journal-title":"Vaccine"},{"issue":"28","key":"ref6","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1016\/j.vaccine.2010.04.039","article-title":"Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection","volume":"28","author":"S Jagu","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1521-6616(03)00120-7","article-title":"Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers","volume":"108","author":"CO Tacket","year":"2003","journal-title":"Clin Immunol"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"6519","DOI":"10.1128\/IAI.72.11.6519-6527.2004","article-title":"Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes","volume":"72","author":"EH Nardin","year":"2004","journal-title":"Infection and immunity"},{"issue":"9447","key":"ref9","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"DM Harper","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jaci.2006.01.040","article-title":"Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults","volume":"117","author":"TM Kundig","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"46","key":"ref11","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.1016\/j.vaccine.2014.08.079","article-title":"Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines","volume":"32","author":"BJ Ward","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clim.2014.08.003","article-title":"Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens","volume":"154","author":"N Landry","year":"2014","journal-title":"Clin Immunol"},{"issue":"39","key":"ref13","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2014.07.011","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers","volume":"32","author":"JG Low","year":"2014","journal-title":"Vaccine"},{"issue":"44","key":"ref14","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1016\/j.vaccine.2011.07.099","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico","volume":"29","author":"C Lopez-Macias","year":"2011","journal-title":"Vaccine"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","first-page":"10945","DOI":"10.1128\/JVI.05406-11","article-title":"H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans","volume":"85","author":"S Khurana","year":"2011","journal-title":"J Virol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"e15559","DOI":"10.1371\/journal.pone.0015559","article-title":"Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza","volume":"5","author":"N Landry","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"M Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3 Suppl","key":"ref18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses","volume":"115","author":"MP David","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1017\/S0022172400028990","article-title":"A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity","volume":"90","author":"A Clark","year":"1983","journal-title":"J Hyg (Lond)"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jmv.1890170405","article-title":"Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine","volume":"17","author":"PR Johnson Jr.","year":"1985","journal-title":"Journal of medical virology"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/JCM.23.1.66-72.1986","article-title":"Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine","volume":"23","author":"ML Clements","year":"1986","journal-title":"Journal of clinical microbiology"},{"issue":"14","key":"ref22","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0264-410X(96)00058-8","article-title":"Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults","volume":"14","author":"WE Beyer","year":"1996","journal-title":"Vaccine"},{"issue":"10","key":"ref23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0264-410X(97)00003-0","article-title":"Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period","volume":"15","author":"WA Keitel","year":"1997","journal-title":"Vaccine"},{"issue":"39","key":"ref24","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.vaccine.2009.06.082","article-title":"Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus","volume":"27","author":"GV Zuccotti","year":"2009","journal-title":"Vaccine"},{"issue":"37\u201338","key":"ref25","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1016\/j.vaccine.2007.07.013","article-title":"Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma","volume":"25","author":"G Zuccotti","year":"2007","journal-title":"Vaccine"},{"issue":"23","key":"ref26","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1016\/j.vaccine.2010.03.067","article-title":"Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence","volume":"28","author":"JY Song","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.7774\/cevr.2013.2.2.115","article-title":"Long-term immunogenicity of the influenza vaccine at reduced intradermal and full intramuscular doses among healthy young adults","volume":"2","author":"JY Song","year":"2013","journal-title":"Clin Exp Vaccine Res"},{"issue":"7","key":"ref28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/21645515.2015.1037998","article-title":"Immunological persistence of a seasonal influenza vaccine in people more than 3 years old","volume":"11","author":"Y Bai","year":"2015","journal-title":"Human vaccines & immunotherapeutics"},{"key":"ref29","article-title":"Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination","author":"JG Petrie","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1750-2659.2012.00349.x","article-title":"An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults","volume":"7","author":"P Gillard","year":"2013","journal-title":"Influenza and other respiratory viruses"},{"issue":"43","key":"ref31","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1016\/j.vaccine.2012.07.077","article-title":"Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming","volume":"30","author":"MV van der Velden","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","article-title":"H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses","volume":"31","author":"P Moris","year":"2011","journal-title":"Journal of clinical immunology"},{"issue":"19","key":"ref33","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"G Galli","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ref34","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"KR Talaat","year":"2014","journal-title":"J Infect Dis"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1128\/CVI.00626-12","article-title":"Combined administration of MF59-adjuvanted A\/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule","volume":"20","author":"P Lopez","year":"2013","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4161\/hv.19684","article-title":"Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years","volume":"8","author":"A Saitoh","year":"2012","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/INF.0b013e31825e6cd6","article-title":"Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity","volume":"31","author":"JM Langley","year":"2012","journal-title":"The Pediatric infectious disease journal"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.4161\/hv.21081","article-title":"Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older","volume":"8","author":"H Ikematsu","year":"2012","journal-title":"Human vaccines & immunotherapeutics"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.rinim.2012.10.001","article-title":"The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine: Randomized, observer-masked, single-center clinical study","volume":"2","author":"Z Yang","year":"2012","journal-title":"Results Immunol"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1128\/CVI.00026-12","article-title":"Comparison of the long-term immunogenicity of two pandemic influenza A\/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults. Clinical and vaccine immunology","volume":"19","author":"JY Song","year":"2012","journal-title":"CVI"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.4161\/hv.29393","article-title":"A dose-ranging study of MF59((R))-adjuvanted and non-adjuvanted A\/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination","volume":"10","author":"KS Reisinger","year":"2014","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4161\/hv.22421","article-title":"Antibody persistence after Pandemic H1N1 2009 influenza vaccination among healthcare workers in Pune, India","volume":"9","author":"BV Tandale","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"33","key":"ref43","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1016\/j.vaccine.2015.05.081","article-title":"Persistence and avidity maturation of antibodies to A(H1N1)pdm09 in healthcare workers following repeated annual vaccinations","volume":"33","author":"S Eidem","year":"2015","journal-title":"Vaccine"},{"issue":"32","key":"ref44","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2012.05.013","article-title":"A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A\/H1N1 influenza vaccine in adult and elderly populations","volume":"30","author":"C Hatz","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1080\/21645515.2015.1063754","article-title":"Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies","volume":"11","author":"J Garcia-Sicilia","year":"2015","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"9","key":"ref46","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1128\/CVI.05046-11","article-title":"Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population","volume":"18","author":"E Huijskens","year":"2011","journal-title":"Clinical and vaccine immunology: CVI"},{"key":"ref47","article-title":"Global epidemiological surveillance standards for influenza","year":"2013"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4161\/hv.24504","article-title":"Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18\u201360 years and older","volume":"9","author":"P Van Damme","year":"2013","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1128\/CVI.00725-12","article-title":"Long-term immunogenicity of the pandemic influenza A\/H1N1 2009 vaccine among health care workers: influence of prior seasonal influenza vaccination","volume":"20","author":"JY Song","year":"2013","journal-title":"Clinical and vaccine immunology: CVI"},{"issue":"23","key":"ref50","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2012.03.017","article-title":"A randomized clinical trial to identify the optimal antigen and MF59((R)) adjuvant dose of a monovalent A\/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects","volume":"30","author":"C Hatz","year":"2012","journal-title":"Vaccine"},{"issue":"27","key":"ref51","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1016\/j.vaccine.2012.04.020","article-title":"One dose of an MF59-adjuvanted pandemic A\/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies","volume":"30","author":"E Faenzi","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.arcmed.2012.09.005","article-title":"Epidemiological characterization of a fourth wave of pandemic A\/H1N1 influenza in Mexico, winter 2011\u20132012: age shift and severity","volume":"43","author":"VH Borja-Aburto","year":"2012","journal-title":"Arch Med Res"},{"issue":"25\u201326","key":"ref53","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2009.01.070","article-title":"Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines","volume":"27","author":"S Gross","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"ref54","doi-asserted-by":"crossref","first-page":"e2975","DOI":"10.1371\/journal.pone.0002975","article-title":"Influence of prior influenza vaccination on antibody and B-cell responses","volume":"3","author":"S Sasaki","year":"2008","journal-title":"PLoS One"},{"issue":"7","key":"ref55","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2009.12.014","article-title":"Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial","volume":"28","author":"F Roman","year":"2010","journal-title":"Vaccine"},{"issue":"5937","key":"ref56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.1176225","article-title":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans","volume":"325","author":"RJ Garten","year":"2009","journal-title":"Science"},{"issue":"23","key":"ref57","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"GM Li","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref58","first-page":"139","article-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","volume":"xii","year":"2011"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1590\/S1135-57272004000200013","article-title":"Epidat 3.0 programa para an\u00e1lisis epidemiol\u00f3gico de datos tabulados","volume":"78","author":"X Hervada Vidal","year":"2004","journal-title":"Revista Espa\u00f1ola De Salud P\u00fablica"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1590\/S1020-49892010000100012","article-title":"El programa epidat: usos y perspectivas","volume":"27","author":"MI Santiago P\u00e9rez","year":"2010","journal-title":"Revista Panamericana De Salud P\u00fablica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0150146","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T04:19:27Z","timestamp":1600229967000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0150146"}},"subtitle":[],"editor":[{"given":"Florian","family":"Krammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,2,26]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0150146","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,26]]}}}